Snapshot from Jul 19, 2026 at 14:14 UTC. For live data and tracking: View Live
Events / Regulatory / MHRA Approves INmune Bio Ebstrocel PIP
Regulatory regulatory approval

MHRA Approves INmune Bio Ebstrocel PIP

Analysis based on 6 articles · First reported Jun 25, 2026 · Last updated Jun 25, 2026

Sentiment
70
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The approval of the Pediatric Investigation Plan (PIP) by the United Kingdom — Medicines and Healthcare products Regulatory Agency (MHRA) for INmune Bio Inc.'s Ebstrocel significantly de-risks the regulatory pathway for the drug in the United Kingdom. This milestone is expected to positively impact INmune Bio Inc.'s stock price due to reduced regulatory uncertainty and accelerated potential market access, creating a value inflection opportunity for shareholders.

biotechnology pharmaceuticals
Event Summary

The United Kingdom — Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has approved INmune Bio Inc.'s Pediatric Investigation Plan (PIP) for Ebstrocel, a treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB). This approval, achieved in under three months, validates the clinical data package and accelerates the regulatory path for Ebstrocel, a product of the CORDStrom platform. The company plans to file a Marketing Authorization Application (MAA) in the United Kingdom and European Union in 2026, and a U.S. Biologics License Application (BLA) in early 2027. This regulatory milestone is considered a significant de-risking event for INmune Bio Inc., positioning the company closer to potential commercialization and creating value for shareholders.

Entities Involved
stock
INmune Bio
INmune Bio Inc. received approval for its Pediatric Investigation Plan (PIP) for Ebstrocel, accelerating its regulatory path in the United Kingdom and de-risking its CORDStrom platform. This positions the company for potential market authorization and commercialization, creating a significant value opportunity for shareholders.
Importance 100.0 Sentiment 75.0
govactor
United Kingdom — Medicines and Healthcare products Regulatory Agency
The United Kingdom — Medicines and Healthcare products Regulatory Agency (MHRA) approved INmune Bio Inc.'s Pediatric Investigation Plan (PIP) for Ebstrocel, validating the clinical data and accelerating the regulatory process in the United Kingdom. The MHRA's constructive advice and timely review are crucial for the drug's path to market.
Importance 80.0 Sentiment 0.0
cnt
United Kingdom
The United Kingdom is the first country where INmune Bio Inc. has received a key regulatory approval for Ebstrocel, paving the way for a Marketing Authorization Application (MAA) and potential market access for patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB).
Importance 60.0 Sentiment 0.0
govactor
European Union — European Medicines Agency
The European Union — European Medicines Agency (EMA) is mentioned as a target for a Marketing Authorization Application (MAA) in 2026 for INmune Bio Inc.'s CORDStrom platform, indicating future regulatory efforts in the European Union.
Importance 30.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration (FDA) is a target for a Biologics License Application (BLA) submission in early 2027 for INmune Bio Inc.'s CORDStrom platform, indicating future regulatory efforts in the United States. The FDA also granted Fast Track designation for XPro1595.
Importance 30.0 Sentiment 0.0
cnt
United States
The United States is a target for a Biologics License Application (BLA) submission in early 2027 for INmune Bio Inc.'s CORDStrom platform, indicating future regulatory efforts in the country.
Importance 30.0 Sentiment 0.0
alliance
European Union
The European Union is a target for a Marketing Authorization Application (MAA) in 2026 for INmune Bio Inc.'s CORDStrom platform, indicating future regulatory efforts in the region.
Importance 30.0 Sentiment 0.0
per
Mark Lowdell
Mark Lowdell, Chief Scientific Officer of INmune Bio Inc., commented on the accelerated review and approval of the PIP by the MHRA, highlighting the critical unmet need in RDEB and the endorsement of the clinical data package.
Importance 20.0 Sentiment 0.0
per
David Moss
David Moss, CEO of INmune Bio Inc., emphasized the significance of the PIP approval as a regulatory de-risking milestone for Ebstrocel and the CORDStrom platform, providing a clear roadmap for potential approval and commercialization.
Importance 20.0 Sentiment 0.0
Relationships
United Kingdom — Medicines and Healthcare products Regulatory Agency related ↔ United Kingdom
United Kingdom — Medicines and Healthcare products Regulatory Agency related ↔ European Union — European Medicines Agency
United Kingdom — Medicines and Healthcare products Regulatory Agency related ↔ United States — Food and Drug Administration
United Kingdom related ↔ European Union — European Medicines Agency
United Kingdom related ↔ United States — Food and Drug Administration
United Kingdom allies ↔ United States The United Kingdom is a longstanding defense and trade ally of the United States, though it has recently restricted US u
United Kingdom related ↔ European Union
European Union — European Medicines Agency related ↔ United States — Food and Drug Administration
European Union — European Medicines Agency related ↔ United States
European Union — European Medicines Agency related ↔ European Union
United States — Food and Drug Administration related ↔ United States
United States — Food and Drug Administration related ↔ European Union
United States related ↔ European Union
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.